Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Siegal

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Blood Advances|June 11, 2026
Effect of PCC on Thrombin Generation in Patients on FXaI with Bleeding or Needing Urgent Surgery (GAUGE)Joseph R Shaw, Hannah Gray, Yan Xu, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2025
The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trialNick van Es, Luuk J J Scheres, Kristen M Sanfilippo, et al.
Pilot and Feasibility Studies|August 2, 2022
Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trialAnne M Holbrook, Kristina Vidug, Lindsay Yoo, et al.
Journal of Thrombosis and Haemostasis : JTH|April 27, 2025
Venous thromboembolism after hospitalization for COVID-19: venous thrombosis virtual surveillance in COVID) studyDeborah M Siegal, Marie-Pier Arsenault, Jameel Abdulrehman, et al.
JAMA Cardiology|November 12, 2025
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical TrialDeborah M Siegal, Christian Sticherling, Jeff S Healey, et al.
Journal of Thrombosis and Haemostasis : JTH|February 7, 2026
Surgical and Procedural Bleed Risk Stratification for Anticoagulated Patients Undergoing Planned Surgery: Guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and HemostasisJoseph R Shaw, Jameel Abdulrehman, Steffan Frosi Stella, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
JAMA Cardiology|June 1, 2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A ReviewBehnood Bikdeli, Farbod Zahedi Tajrishi, Parham Sadeghipour, et al.
Journal of the American College of Cardiology|January 17, 2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art ReviewAntoine Bejjani, Candrika D Khairani, Ali Assi, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Blood Advances|June 11, 2026
Effect of PCC on Thrombin Generation in Patients on FXaI with Bleeding or Needing Urgent Surgery (GAUGE)Joseph R Shaw, Hannah Gray, Yan Xu, et al.
Journal of Thrombosis and Haemostasis : JTH|December 21, 2025
The win ratio for evaluating edoxaban versus dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE cancer trialNick van Es, Luuk J J Scheres, Kristen M Sanfilippo, et al.
Pilot and Feasibility Studies|August 2, 2022
Coordination of Oral Anticoagulant Care at Hospital Discharge (COACHeD): protocol for a pilot randomised controlled trialAnne M Holbrook, Kristina Vidug, Lindsay Yoo, et al.
Journal of Thrombosis and Haemostasis : JTH|April 27, 2025
Venous thromboembolism after hospitalization for COVID-19: venous thrombosis virtual surveillance in COVID) studyDeborah M Siegal, Marie-Pier Arsenault, Jameel Abdulrehman, et al.
JAMA Cardiology|November 12, 2025
Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical TrialDeborah M Siegal, Christian Sticherling, Jeff S Healey, et al.
Journal of Thrombosis and Haemostasis : JTH|February 7, 2026
Surgical and Procedural Bleed Risk Stratification for Anticoagulated Patients Undergoing Planned Surgery: Guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and HemostasisJoseph R Shaw, Jameel Abdulrehman, Steffan Frosi Stella, et al.
The New England Journal of Medicine|August 31, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Truman J Milling, John W Eikelboom, et al.
JAMA Cardiology|June 1, 2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A ReviewBehnood Bikdeli, Farbod Zahedi Tajrishi, Parham Sadeghipour, et al.
Journal of the American College of Cardiology|January 17, 2024
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art ReviewAntoine Bejjani, Candrika D Khairani, Ali Assi, et al.
The New England Journal of Medicine|February 8, 2019
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa InhibitorsStuart J Connolly, Mark Crowther, John W Eikelboom, et al.
Pageof 13